CardioSignal collaborates with Mehiläinen to advance early detection of atrial fibrillation with digital health solutions
To enable the early detection of atrial fibrillation and subsequent intervention, Mehiläinen and CardioSignal are collaborating to build a digital health approach that includes offering home monitoring to at-risk individuals in Finland. Early detection of atrial fibrillation has the potential to significantly reduce future hospitalizations from heart failure or stroke.
Mehiläinen is a private healthcare and social services provider, offering comprehensive, high-quality services to private, corporate and municipal customers, serving around 1.3 million individuals.
In Mehiläinen’s customer base, CardioSignal, an easy-to-use atrial fibrillation detection application, is offered to 10,000 at-risk individuals for regular home monitoring. In spring 2021, the companies piloted the concept with promising results: In a group of approximately 3,000 people, new atrial fibrillation was detected in 1% of individuals.
“On Mehiläinen’s lifelong mission, I am very glad that we can take this remarkable step of growth and development together with CardioSignal. Digital healthcare needs strong and skillful partnerships to bring the best knowledge together and deliver high-quality and effective digital tools to our patients. This initiative definitely brings value on a broad scale to both our healthcare professionals and our customers,” says Medical Director, Private Healthcare, Iiro Heikkilä from Mehiläinen. “CardioSignal is an excellent example of how digital medical devices can play a major role in a patient’s path to diagnosis and treatment,” he adds.
“The digital care path will be a game changer in the diagnosis and management of atrial fibrillation in at-risk populations. CardioSignal offers an effective and safe strategy to identify patients who need further examination and management by healthcare providers. We are proud to support Mehiläinen in their effort to offer innovative and clinically impactful digital health solutions to their customers,” says CardioSignal’s CEO, cardiologist Juuso Blomster.
Atrial fibrillation is the most common heart rhythm disorder, it is dangerously asymptomatic, and its prevalence is on the rise. When left untreated, it can cause serious health outcomes, such as ischemic stroke and heart failure.
About the initiative:
A collaborative effort between Mehiläinen and CardioSignal in Finland
The goal is to reach approximately 10,000 individuals
Begins in February 2022, individuals will be offered access to CardioSignal until the end of 2022
Targeted at individuals over 50 or who have a risk factor for atrial fibrillation (for example, high blood pressure, other existing heart conditions, sleep apnea, diabetes and asthma)
Further information:
CardioSignal
Juuso Blomster, CEO, juuso.blomster@cardiosignal.com
Juulia Simonen (Communications) juulia.simonen@cardiosignal.com, tel. +358503059018
Mehiläinen
Iiro Heikkilä, iiro.heikkila@mehilainen.fi
Salla Tähtinen (Communications), salla.tahtinen@mehilainen.fi.
About CardioSignal
We develop groundbreaking solutions for the detection of heart diseases. CardioSignal is a mobile application and a certified medical device for the detection of atrial fibrillation. Originally an academic spinoff, the company’s patented technology is built on a decade of research and algorithm development. CardioSignal is a brand and a product by Precordior. www.cardiosignal.com
About Mehiläinen
Mehiläinen is a well-known and highly valued private provider of health care and social services in Finland, offering comprehensive high-quality services quickly and smoothly to private, corporate and municipal customers. Mehiläinen provides help, support and care to around 1.3 million customers annually. Mehiläinen’s services are produced at over 540 locations by more than 22,300 employees and private practitioners. www.mehilainen.com.
